Explaining lung fibrosis: Crown Princess Mette-Marit's condition and treatment options

Crown Princess Mette-Marit of Norway is facing a significant health challenge as she undergoes treatment for lung fibrosis, a chronic and progressive lung disease. While the Norwegian Royal House has not specified the exact type of lung fibrosis the Crown Princess has, the condition involves the gradual replacement of healthy lung tissue with stiff scar tissue, impairing the lungs' ability to transfer oxygen.

Lung fibrosis affects approximately 7,000 people in Sweden, with idiopathic lung fibrosis (of unknown cause) being the most common form. Risk factors include smoking, exposure to harmful substances like asbestos or mold, and certain autoimmune diseases such as rheumatoid arthritis. Symptoms typically include shortness of breath, a dry cough, and sometimes bluish discoloration of the lips and swollen fingers.

Historically, lung fibrosis carried a grim prognosis, with a median survival of three to five years for those with idiopathic lung fibrosis. However, medical advancements have significantly improved outcomes. Treatments now focus on slowing the scarring process with medication, managing symptoms through oxygen therapy and rehabilitation programs, and, in severe cases, lung transplantation. Many patients now live a decade or more after diagnosis.

Lung transplantation is considered for patients with rapidly deteriorating lung function who are otherwise healthy. Globally, around 4,000 lung transplants are performed annually. While survival rates after transplantation are encouraging, with over 70% of patients living five years post-operation, the procedure carries risks such as infection and organ rejection. The availability of donor organs also remains a limiting factor.